Accuracy of target-controlled infusion (TCI) with 2 different propofol formulations

被引:0
作者
Ihmsen, H [1 ]
Jeleazcov, C [1 ]
Schüttler, J [1 ]
Schwilden, H [1 ]
Bremer, F [1 ]
机构
[1] Univ Erlangen Nurnberg, Anasthesiol Klin, D-91054 Erlangen, Germany
来源
ANAESTHESIST | 2004年 / 53卷 / 10期
关键词
propofol; formulation; target-controlled infusion (TCI); pharmacokinetics; cross-over study;
D O I
10.1007/s00101-004-0753-6
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Target-controlled infusion (TCI) of propofol was initially realized as a device for prefilled syringes (Diprifusor(R)). New TCI systems can be used with any propofol formulation. We compared two different propofol formulations with respect to accuracy of TCI and pharmacokinetics. Materials and met hods. A total of 10 volunteers received Diprivan(R) 1% and Propofol 1% MCT Fresenius(R) as TO using the pharmacokinetic model of the Diprifusor(R). The prediction error was determined from measured arterial concentrations. A three-compartment model was fitted to the concentration data. Results. The median prediction error and the median absolute prediction error were -1.4% and 23.3% for Diprivan(R), and -5.9% and 17.8% for Propofol Fresenius(R). The drugs did not differ in pharmacokinetics but showed a smaller central volume of distribution than used for infusion control. Conclusions. The pharmacokinetic model of Diprifusor(R) can also be used for TCI of Propofol Fresenius(R). The large volume of distribution in this model may cause an overshoot in concentration.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 20 条
[1]   Current and future applications of target-controlled infusions [J].
Absalom, A ;
Kenny, GNC .
DRUGS OF TODAY, 1999, 35 (11) :823-834
[2]   PHARMACOKINETIC MODEL SELECTION FOR TARGET CONTROLLED INFUSIONS OF PROPOFOL - ASSESSMENT OF 3 PARAMETER SETS [J].
COETZEE, JF ;
GLEN, JB ;
WIUM, CA ;
BOSHOFF, L .
ANESTHESIOLOGY, 1995, 82 (06) :1328-1345
[3]   Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol [J].
Cox, EH ;
Knibbe, CAJ ;
Koster, VS ;
Langemeijer, MWE ;
Tukker, EE ;
Lange, R ;
Kuks, PFM ;
Langemeijer, HJM ;
Lie-A-Huen, L ;
Danhof, M .
PHARMACEUTICAL RESEARCH, 1998, 15 (03) :442-448
[4]   Pharmacokinetics and pharmacodynamics of propofol in a new solvent [J].
Doenicke, AW ;
Roizen, MF ;
Rau, J ;
OConnor, M ;
Kugler, J ;
Klotz, U ;
Babl, J .
ANESTHESIA AND ANALGESIA, 1997, 85 (06) :1399-1403
[5]   Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats [J].
Dutta, S ;
Ebling, WF .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (01) :37-42
[6]   The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol®) versus propofol in a lipid formulation (Diprivano®):: An electroencephalographic and hemodynamic study in a porcine model [J].
Egan, TD ;
Kern, SE ;
Johnson, KB ;
Pace, NL .
ANESTHESIA AND ANALGESIA, 2003, 97 (01) :72-79
[7]  
Fechner J, 1998, ANAESTHESIST, V47, P663, DOI 10.1007/s001010050611
[8]  
GEPTS E, 1987, ANESTH ANALG, V66, P1256
[9]   Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery [J].
Knibbe, CAJ ;
Aarts, LPHJ ;
Kuks, PFM ;
Voortman, HJ ;
Lie-A-Huen, L ;
Bras, LJ ;
Danhof, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) :89-95
[10]   HEPATIC AND EXTRAHEPATIC DISPOSITION OF PROPOFOL IN PATIENTS UNDERGOING CORONARY-BYPASS SURGERY [J].
LANGE, H ;
STEPHAN, H ;
RIEKE, H ;
KELLERMANN, M ;
SONNTAG, H ;
BIRCHER, J .
BRITISH JOURNAL OF ANAESTHESIA, 1990, 64 (05) :563-570